| First Author | Cox AD | Year | 2012 |
| Journal | Cancer Cell | Volume | 21 |
| Issue | 2 | Pages | 147-9 |
| PubMed ID | 22340588 | Mgi Jnum | J:181465 |
| Mgi Id | MGI:5311489 | Doi | 10.1016/j.ccr.2012.01.017 |
| Citation | Cox AD, et al. (2012) The RAF Inhibitor Paradox Revisited. Cancer Cell 21(2):147-9 |
| abstractText | The success of the RAF protein kinase inhibitor vemurafenib for the treatment of BRAF mutant metastatic melanoma has produced another poster child for the promise of personalized medicine. However, the results of a recent study also reveal unexpected pitfalls in the application of signal transduction-targeted therapies. |
